Under the one-year award, the South Carolina-headquartered company's real-time streaming telemedicine platform will be used with its integrated wearable sensor kit to monitor heart rate variability.
Heart rate variability, or HRV, is an important biomarker that can be used to help regulate the autonomic nervous system, attentiveness and emotional responses.
HRV can be monitored and studied in out-of-the-laboratory settings using the company devices, improving research and the understanding of treatment options, Zeriscope said.
"Zeriscope technology may facilitate more objective evaluation of treatment impact that can also be correlated with patient outcomes," said Dr. Michael Jenkins-Guarnieri, a TBI researcher at Madigan Army Medical Center. "Further, this technology could become a useful tool to evaluate novel treatment modalities in the future."
The monetary value of the contract for the Army Advanced Medical Technology Initiative was not disclosed.
Zeriscope describes itself as a mobile telemedicine platform company. It facilitates live, secure, online, video-enabled telemedicine exams.
| The content herein, unless otherwise known to be public domain, is Copyright 1995-2026 Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principles for news reporting and research purposes. |
